Roger SD, Lavin PT, Lerma EV, et al. - In this post hoc analysis of an open-label, single-arm trial involving 751 patients, researchers sought to compare sodium zirconium cyclosilicate (SZC; formerly ZS-9) effectiveness and safety > 12 months among outpatients with hyperkalaemia and Stages 4 and 5 chronic kidney disease (CKD) vs those with Stages 1–3 CKD. For this analysis, adults with serum K⁺ ≥ 5.1 mmol/L received SZC 10 g three times daily for 24–72 h until normokalaemia was achieved. Across the MP, mean serum K⁺ reduction from baseline was maintained during the CP, and serum bicarbonate increased. Among outpatients irrespective of the CKD stage, SZC corrects hyperkalaemia and maintains normokalaemia. Constipation, nausea, and peripheral oedema were the most common treatment-related individual adverse events in both the eGFR < 30 and ≥ 30 mL/min/1.73 m² subgroups.